Research progress on the role of lipoprotein- associated phospholipase A2 in acute coronary syndrome

doi:10.16352/j.issn.1001-6325.2024.01.0103

Abstract

Abstract: Lipoprotein-associated phospholipase A2(Lp-PLA2) is a protein composed of 441 amino acids, which can promote the aggregation of inflammatory cells to the inflammatory response site and the release of inflammatory factors. It can promote the synthesis of matrix metalloproteinases, increase the number of foam cells and extra cellular matrix in atherosclerotic plaque, attenuate plaque fiber cap and prone to rupture, thus promote the onset of acute coronary syndrome(ACS). Therefore, the determination and regulation of Lp-PLA2 levels in patients with ACS are clinically significant.

Key words: lipoprotein-associated phospholipase A2, acute coronary syndrome, atherosclerosis

CLC Number:

R541.4

GUO Jianhong, WANG Yaling, CUI Wenguang. Research progress on the role of lipoprotein- associated phospholipase A2 in acute coronary syndrome[J]. Basic & Clinical Medicine, 2024, 44(1): 103-107.

References 25

[1]	Ma S, Ding L, Cai M, et al. Association Lp-PLA2 gene polymorphisms with coronary heart disease[J]. Dis Markers, 2022, 2022: 9775699. doi: 10.1155/2022/9775699. eCollection 2022.
[2]	Zhuo S, Yuan C. Active site competition is the mechanism for the inhibition of lipoprotein-associated phospholipase A(2) by detergent micelles or lipoproteins and for the efficacy reduction of darapladib[J]. Sci Rep, 2020, 10: 17232. doi: 10.1038/s41598-020-74236-0.
[3]	Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Purification and properties[J]. J Biol Chem, 1987, 262: 4223-4230.
[4]	Wojcicka G, Zareba M, Warpas A, et al. The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydro-lase (PAF-AH) activity and concentration in normal and fructose-fed rats[J]. Eur J Pharmacol, 2019, 850:180-189. doi: 10.1016/j.ejphar.2019.02.014.
[5]	Lv SL, Zeng ZF, Gan WQ, et al. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation[J]. Acta Pharmacol Sin, 2021, 42: 2016-2032. doi: 10.1038/s41401-021-00703-7.
[6]	Kim SR, Heo JI, Park JW, et al. Radiation-induced lipoprotein-associated phospholipase A2 increases lysophosphatidylcholine and induces endothelial cell damage[J]. Toxicology, 2021, 458: 152841. doi: 10.1016/j.tox.2021.152841.
[7]	Mourouzis K, Siasos G, Oikonomou E, et al. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunc-tion and arterial stiffness in patients with stable coronary artery disease[J]. Lipids Health Dis, 2021, 20: 12. doi: 10.1186/s12944-021-01438-4.
[8]	Hu HJ, Qiu J, Zhang C, et al. Hydrogen sulfide improves ox-LDL-induced expression levels of Lp-PLA(2) in THP-1 monocytes via the p38MAPK pathway[J]. Mol Med Rep, 2021, 23: 358. doi: 10.3892/mmr.2021.11997.
[9]	刘琴, 杨黎星, 石婧, 等. 小檗碱激活巨噬细胞自噬并改善动脉粥样硬化斑块脆弱性[J].基础医学与临床, 2020, 40: 668-677.
[10]	Zhang H, Zhou W, Cao C, et al. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40[J]. PLoS One, 2018, 13: e0202797. doi: 10.1371/journal.pone.0202797.
[11]	Chandra S, Nagar S, Shukla A, et al. Correlation of lipoprotein (a) levels and plaque morphology in very young acute coronary syndrome patients using optical coherence tomography[J]. Indian Heart J, 2022, 74: 357-362. doi: 10.1016/j.ihj.2022.09.001.
[12]	陈四华, 孙旭晖, 袁强. 血清高敏 C 反应蛋白、脂蛋白相关磷脂酶 A2 水平与高血压合并冠状动脉粥样硬化性心脏病患者冠状动脉罪犯血管纤维脂质斑块纤维帽厚度的相关性[J]. 中华高血压杂志, 2020, 28: 676-679.
[13]	Meng PN, Yin DL, Lu WQ, et al. Intensive statin versus low-dose statin + ezetimibe treatment for fibrous cap thickness of coronary vulnerable plaques[J]. Chin Med J (Engl), 2020, 133: 2415-2421.
[14]	张显敏, 梁琳. 血浆脂联素、脂蛋白相关磷脂酶 A2 检测联合颈动脉超声检查对冠状动脉易损斑块的诊断价值[J]. 陕西医学杂志, 2022, 51: 713-716.
[15]	Zhang L, Li Z, Li N. Serum IMA and LP-PLA2 levels in patients with coronary heart disease and their correlation with the degree of myocardial ischaemia and their diagnostic value[J]. Emerg Med Int, 2022, 2022: 1698315.doi:10.1155/2022/1698315.
[16]	Yang F, Ma L, Zhang L, et al. Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study[J]. Heart Vessels, 2019, 34: 1608-1614.
[17]	Wang R, Wang X, Zhang E, et al. Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease [J]. Am J Transl Res, 2021, 13: 8997-9004.
[18]	李爱华, 张社兵, 徐新, 等. 血清缺血修饰白蛋白、内皮糖蛋白和脂蛋白相关磷脂酶A2表达特征与急性冠状动脉综合征患者危险分层相关性[J]. 临床军医杂志, 2021, 49: 1152-1154.
[19]	叶斐, 王腾, 于宗良. 阿托伐他汀联合依折麦布对急性冠状动脉综合征患者白细胞分化抗原40配体、脂蛋白相关磷脂酶A2和心功能的影响[J]. 心脑血管病防治, 2022, 22: 37-40.
[20]	Qian K, Chen Q, Ding H, et al. Effects of Danhong injection combined with tirofiban on cardiac function, myocardial enzyme spectrum and lipoprotein-associated phospholipase A2 level in patients with acute myocardial infarction[J]. Am J Transl Res. 2022, 14: 7951-7959.
[21]	Baziar N, Nasli-Esfahani E, Djafarian K, et al. The beneficial effects of alpha lipoic acid supplementation on Lp-PLA2 mass and its distribution between HDL and apoB-containing lipoproteins in type 2 diabetic patients: a randomized, double-blind, placebo-controlled trial[J]. Oxid Med Cell Longev, 2020, 2020: 5850865. doi: 10.1155/2020/5850865.
[22]	谢杰, 李拥军. 急性心肌梗死病人血清PLA2和Hcy水平与心室重构的关系[J]. 中西医结合心脑血管病杂志, 2021, 19: 4120-4123.
[23]	刘佳良, 郭黎平, 乔举伟. 血清LP-PLA2、MCP-1水平与ST段抬高型心肌梗死患者PCI后心力衰竭发生的关系[J]. 医药论坛杂志, 2022, 43: 80-82.
[24]	Sheng G, Zhou J, Zhang C, et al. Relationship between Lp-PLA2 and in-stent restenosis after coronary stenting: a 3-year follow-up study[J]. Scott Med J, 2021, 66: 178-185.
[25]	Norata GD, Woudstra P, Damman P, et al. Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction[J]. PLoS One, 2014, 9: e96251.doi: 10.1371/journal.pone.0096251.